Regeneron has declined 26.5% over this time frame, while the broader S&P 500 Index has soared 20.7%. Moreover, the stock is down 1.7% on a YTD basis, compared to SPX’s 2.2% gain during the same ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the Best Non-Mega Cap NASDAQ Stocks to Buy Right Now. UBS analyst ...

Debt Management: Regeneron Pharmaceuticals's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.1. The Significance of Analyst Ratings Explained ...

Analysts have recently evaluated Regeneron Pharmaceuticals and provided 12-month price targets. The average target is $769.35, accompanied by a high estimate of $975.00 and a low estimate of $547.00.

Bernstein cuts Regeneron stock price target to $1,000, keeps Outperform. 3mo. ... REGN) to $1,000 from the previous $1,070, while retaining an Outperform rating on the stock.

Regeneron Pharmaceuticals (NASDAQ:REGN) has observed the following analyst ratings within the last quarter: According to 13 analyst offering 12-month price targets in the last 3 months, Regeneron ...

Regeneron Pharmaceuticals sees strength in Dupixent, oncology gains, and major buybacks despite setbacks. Find out why REGN ...

Kiniksa stock rocketed 20% after first-quarter results on April 29. The biotech stock then broke out of a cup base with a buy point of 28.15 on May 5. IBD MarketSurge shows that shares traded tightly ...

Regeneron's Dupixent leads growth as Eylea sales decline and valuation is attractive, but growth is delayed by 2-3 years. Learn more on REGN stock here.

Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are ...